Teva Pharmaceutical Indus에 대한 매도 수량은 투자자에게 Teva Pharmaceutical Indus의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Equities

News

Markets

NUKK

QUBT

TEVA

TSLA

화요일(17일) 미국 증시는 11월 소매판매 발표 이후 주요 지수가  하락했다. 소매판매 데이터는 연준의 내년 금리인하 지연 가능성에 대한 우려를 불러일으켰다. 뉴클러스, 마이크론, 테바 파마슈티컬, 퀀텀 컴퓨팅 및 테슬라

화요일 주목받은 주식: 뉴클러스, 마이크론, 테바 파마슈티컬, 퀀텀 컴퓨팅 및 테슬라

Movers

EQIX

TOST

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?테바 파마슈티컬 인더스트리즈(NYSE:TEVA)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 위약과 비교하여 정신분열증이 있는 성인 환자를 대상으로 한 TEV-&#39;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다. 

지난주(5월 5일~5월 11일) 최고의 성과를 낸 10개의 대형주

Earnings

Pre-Market Outlook

Trading Ideas

LYFT

UBER

수요일 오전(현지 시간) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월가는 수요일 개장 전 분기 실적 발표로 에머슨 일렉트릭(NYSE:EMR)이 매출 42억 9천만 달러, 주당 1.25달러의 분기 이익을 보고할 것으로 예상한다. 에머슨 일렉트릭의 주식은 시간외 거래에서 1.2% 오른 108.70달러에 거래되었다. 

우버, 리프트 그리고 수요일에 주목해야 할 3개의 주식

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

Wall Street experienced a downturn on Tuesday as major indices fell following a strong retail sales report for November. The data raised concerns about the Federal Reserve&#8217;s potential delay in cutting interest rates next year. The S&amp;P 500 and Dow Jones Industrial Average dropped by 0.4% and 0.6% respectively, while the Nasdaq 100 declined by 0.3%, with semiconductor stocks leading the losses amid geopolitical tensions.
These are the top stocks that gained the attention of retail traders and investors through the day:
Nukkleus Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)
Nukkleus Inc. saw a significant surge of 754.68%, closing at $11.88. The stock reached an intraday high of $17.66 and a low of $1.84, with a 52-week range of $34.16 to $0.40. This dramatic rise followed the company&#8217;s announcement of acquiring a 51% controlling stake in Star 26 Capital Inc., which holds a substantial share in RIMON, an Israeli supplier for the Iron Dome missile defense system. This acquisition <a href="https://www.benzinga.com/24/12/42535878/why-nukkleus-stock-is-gaining-tuesday">boosts</a> Nukkleus&#8217;s defense ambitions.
Micron Technology Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
Micron Technology Inc. experienced a modest increase of 0.31%, closing at $108.60. The stock fluctuated between a high of $110.49 and a low of $107.68, with a 52-week range of $157.54 to $78.63. The company is set to release its first-quarter financial results, with analysts <a href="https://www.benzinga.com/24/12/42541544/micron-q1-earnings-preview-analyst-estimates-why-company-is-well-positioned-heading-into-2025">expecting revenue</a> to reach $8.72 billion, a significant increase from the previous year. Micron has consistently outperformed revenue estimates in recent quarters.
Teva Pharmaceutical Industries Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)
Teva Pharmaceutical Industries Ltd. saw its stock rise by 26.47%, closing at $20.88. The stock hit an intraday high of $21.05 and a low of $19.03, with a 52-week high of $21.05 and a low of $10. The increase followed the successful completion of a Phase 2b study for a monoclonal antibody targeting inflammatory bowel disease, achieving&nbsp;<a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday">positive</a>&nbsp;results in clinical remission rates.
Quantum Computing Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)
Quantum Computing Inc. shares jumped by 51.53%, closing at $16.79. The stock&#8217;s intraday range was $18.06 to $12.60, with a 52-week high of $18.06 and a low of $0.35. The rise came after the company announced a <a href="https://www.benzinga.com/24/12/42533581/quantum-computing-stock-is-rising-tuesday-heres-why">prime contract</a> with NASA for imaging and data processing support, utilizing its Dirac-3 machine to enhance data quality and accuracy.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla Inc. saw a 3.64% increase, closing at $479.86. The stock reached an intraday high of $483.99 and a low of $457.51, with a 52-week range of $483.99 to $138.8. Analyst Dan Ives predicts that Tesla will be a <a href="https://www.benzinga.com/markets/equities/24/12/42522531/tesla-will-be-the-biggest-winner-in-the-trump-era-says-dan-ives-predicts-nasdaq-at-25000-in-18-months-get-the-popcorn-out">major beneficiary</a> in the tech sector expansion anticipated under President-elect Donald Trump&#8217;s administration, driven by artificial intelligence and deregulation.
Image Via Shutterstock.com
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42485284/billionaire-warren-buffett-paid-120000-for-a-home-but-took-out-a-mortgage-to-do-it-investing-that-money-instead-made-him-2-billion?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Billionaire Warren Buffett Paid $120,000 For A Home But Took Out A Mortgage To Do It – Investing That Money Instead Made Him $2 Billion</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 178.2% to $9.04 during Tuesday's pre-market session. The company's market cap stands at $10.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 137.73% to $1.26. The market value of their outstanding shares is at $235.4 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares rose 39.15% to $8.85. The company's market cap stands at $178.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) stock rose 27.53% to $1.26. The market value of their outstanding shares is at $33.3 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares moved upwards by 19.13% to $19.67. The market value of their outstanding shares is at $22.2 billion. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 17.99% to $1.18. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock decreased by 47.7% to $1.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 38.27% to $1.42. The company's market cap stands at $47.4 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares decreased by 33.49% to $3.0. The market value of their outstanding shares is at $97.7 million. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) stock declined by 31.25% to $1.98. The company's market cap stands at $156.8 million. </li>
<li>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) stock declined by 23.79% to $70.19. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 12.49% to $5.12. The company's market cap stands at $185.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKTX

BMEA

CAMP

LMAT

PEPG

PLRZ

PRTG

RVPH

TNXP

TNYA

VCNX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.
Shares of RCI Hospitality Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/RICK/earnings">quarterly financial results</a>.
RCI Hospitality reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $73.23 million which beat the analyst consensus estimate of $72.98 million.
RCI Hospitality shares surged 15.4% to $60.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares jumped 31.7% to $14.60 after the company announced it was awarded a prime contract by NASA to apply Dirac-3 for imaging and data processing support.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares surged 25.6% to $1.47.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) shares gained 21.7% to $32.20.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) climbed 20% to $19.82 after the company and Sanofi announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn&#8217;s disease.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) gained 20% to $12.16.</li>
<li>Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) gained 17.8% to $12.10.</li>
<li>SelectQuote, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) shares rose 17.3% to $3.2388.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 15% to $2.4494.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) rose 15% to $30.39.</li>
<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) gained 14.2% to $11.60.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 11.3% to $9.38.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 5.3% to $31.01.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) rose 5% to $20.17.</li>
<li>Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) gained 4.8% to $48.08 after the company and Teva announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares rose 3% to $477.19 after Mizuho upgraded the stock from Neutral to Outperform and raised its price target from $230 to $515.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42528919/how-to-earn-500-a-month-from-apple-stock-4">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Intraday Update

ARQQ

BILI

HSAI

JUNS

RGTI

RICK

RZLV

SKYT

SLQT

RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42527140/teva-and-sanofi-announce-duvakitug-anti-tl1a-positive-phase-2b-results-demonstrating-best-in-class" rel="noreferrer noopener">Crohn&#8217;s disease (CD)</a>.
RELIEVE UCCD investigated duvakitug (TEV&#8217;574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD).
In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug</a>
In patients with Crohn&#8217;s disease, 26.1% (low-dose) and 47.8% (high-dose) treated with duvakitug achieved endoscopic response compared to 13.0% on placebo, placebo-adjusted rates were 13.0% (low dose) and 34.8% (high dose).
Overall, the treatment effect was consistent across subgroups.
Detailed results are expected to be presented at a scientific forum in 2025.
Duvakitug was generally well tolerated in ulcerative colitis and Crohn&#8217;s disease, with no safety signal identified.
Overall treatment-emergent adverse events (AE) rates were similar between duvakitug and placebo.
Ulcerative colitis and Crohn&#8217;s disease, the two main types of IBD, are chronic inflammatory conditions of the GI tract resulting in symptoms such as abdominal pain, diarrhea, rectal bleeding, fatigue, and weight loss.
Price Action: At last check Tuesday, TEVA stock was up 20.40% at $19.88, and SNY stock was up 4.07% at $47.76 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42529245/trump-and-netflix-boss-sarandos-set-for-high-stakes-mar-a-lago-meeting" target="_blank" rel="noreferrer noopener">Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting</a></li>
</ul>

Biotech

Large Cap

Health Care

General

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

WIIM

Teva shares are trading higher after the company and Sanofi announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn's disease.

Teva And Sanofi Announce Primary Endpoints Met In Phase 2b Trial Of Duvakitug  In Ulcerative Colitis And Crohn's

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.00</td>
<td>$167.5K</td>
<td>17.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$500.00</td>
<td>$29.9K</td>
<td>1.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$54.7K</td>
<td>6.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$180.00</td>
<td>$292.5K</td>
<td>6.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>VRDN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$22.50</td>
<td>$27.0K</td>
<td>458</td>
<td>599</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$580.00</td>
<td>$57.1K</td>
<td>475</td>
<td>250</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>14</td>
<td>99</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$40.00</td>
<td>$32.6K</td>
<td>615</td>
<td>25</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$25.00</td>
<td>$25.1K</td>
<td>42</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 2500 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $167.5K, with a price of $67.0 per contract. There were 17104 open contracts at this strike prior to today, and today 2970 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 38 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $788.0 per contract. There were 1381 open contracts at this strike prior to today, and today 2262 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 205 contract(s) at a $50.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $54.7K, with a price of $267.0 per contract. There were 6605 open contracts at this strike prior to today, and today 1828 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 760 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $292.5K, with a price of $11700.0 per contract. There were 6297 open contracts at this strike prior to today, and today 1688 contract(s) were bought and sold. 
• For VRDN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.0K, with a price of $135.0 per contract. There were 458 open contracts at this strike prior to today, and today 599 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 56 contract(s) at a $580.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $1020.0 per contract. There were 475 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on January 17, 2025. Parties traded 98 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $460.0 per contract. There were 14 open contracts at this strike prior to today, and today 99 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with neutral sentiment. It expires in 95 day(s) on March 21, 2025. Parties traded 20 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $1630.0 per contract. There were 615 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be neutral, expiring in 151 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $25.1K, with a price of $2517.0 per contract. There were 42 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

PRAX

VKTX

VRDN

9 Health Care Stocks With Whale Alerts In Today's Session

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Galafold patent litigation</a> with Teva Pharmaceutical Industries Ltd.
The analyst notes that Amicus is well-positioned, but expectations have increased with the company&#8217;s progress, which are now largely priced into shares.
The analyst downgraded the stock to Equal-weight from Overweight and lowered the price <a target="_blank" href="https://www.benzinga.com/quote/FOLD/analyst-ratings" rel="noreferrer noopener">target from $17 to $12</a>.
Investors have shifted focus to what will provide the company&#8217;s next leg of growth. The analyst would look to see potential updates to the company&#8217;s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.
Morgan Stanley has also lowered the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40864698/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-patients-w" rel="noreferrer noopener">and ovarian cancer</a>.
The analyst continues to give full credit for Kimmtrak (tebentafusp), which was approved for unresectable or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42282399/immunocore-announces-reimbursement-agreement-in-england-for-kimmtrak-for-the-treatment-of-hla-a-02" rel="noreferrer noopener">metastatic uveal melanoma</a>.
Morgan Stanley sees limited upside potential from additional brenetafusp updates as the company continues to detect signals in metastatic NSCLC and combination in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41769749/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update" rel="noreferrer noopener">earlier-line NSCLC</a>.
The analyst downgraded the stock <a target="_blank" href="https://www.benzinga.com/quote/IMCR/analyst-ratings" rel="noreferrer noopener">from Overweight to Equal-Weight rating.</a>
Morgan Stanley downgraded Immuneering Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares to Underweight from Equal-weight and set a base case range of $1 to $5 versus its <a target="_blank" href="https://www.benzinga.com/quote/IMRX/analyst-ratings" rel="noreferrer noopener">previous target of $4</a>. While supporting Immuneering&#8217;s strategy of targeting the MAPK pathway with deep cyclic inhibition, the analyst notes other stronger investment opportunities in the coverage on a relative basis.
Early clinical results have been promising, but analysts emphasize the need for more robust data with a larger patient pool to confirm that these outcomes aren&#8217;t coincidental or limited to specific cases. Additionally, the analyst expressed greater caution regarding the potential of IMM-1-104 in indications <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40852429/why-is-nanocap-immuneering-stock-trading-higher-on-friday" rel="noreferrer noopener">outside of pancreatic cancer</a>.
Price Action: IMRX stock is down 18% at $1.615, IMCR stock is down 5.89% at $28.53, and FOLD stock is down 6.70% at $9.47 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468572/netflix-adjusts-parental-leave-policy-amid-cultural-and-financial-shifts" target="_blank" rel="noreferrer noopener">Netflix Adjusts Parental Leave Policy, But There Is A Catch</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Downgrades

Price Target

Analyst Ratings

FOLD

IMCR

IMRX

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMED

AMGN

CADL

RXRX

10 Health Care Stocks Whale Activity In Today's Session

<ul>
<li>Teva entered into an agreement with JKI Co., Ltd. ("JKI") established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will"), through which JKI will acquire&nbsp;Teva-Takeda</li>
<li>The agreement is aligned with Teva's Pivot to Growth strategy to focus its business</li>
<li>The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market &nbsp;</li>
</ul>
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.
Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.

Contracts

Global

Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its Business; No Financial Terms Disclosed

<ul>
<li>AJOVY&#xAE; (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1</li>
<li>Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed</li>
<li>Full data presented as a late breaker at European Headache Cosgress (EHC) 4-7 December in Rotterdam, Netherlands</li>
</ul>

Teva Shares Phase 3 SPACE Trial Results Highlighting The Efficacy And Safety Of AJOVY (Fremanezumab) In Preventing Episodic Migraine In Children And Adolescents

High-rolling investors have positioned themselves bearish on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TEVA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 25 options trades for Teva Pharmaceutical Indus. This is not a typical pattern.
The sentiment among these major traders is split, with 24% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $48,400, and 24 calls, totaling $1,648,118.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $17.0 to $30.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teva Pharmaceutical Indus's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teva Pharmaceutical Indus's substantial trades, within a strike price spectrum from $17.0 to $30.0 over the preceding 30 days.
<h3>Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732907733_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.61</td>
<td>$0.23</td>
<td>$0.55</td>
<td>$23.00</td>
<td>$418.3K</td>
<td>30</td>
<td>20.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.4</td>
<td>$0.2</td>
<td>$0.33</td>
<td>$25.00</td>
<td>$117.1K</td>
<td>17</td>
<td>18.5K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$0.45</td>
<td>$0.43</td>
<td>$0.43</td>
<td>$23.00</td>
<td>$107.2K</td>
<td>30</td>
<td>9.9K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.55</td>
<td>$0.23</td>
<td>$0.55</td>
<td>$23.00</td>
<td>$85.2K</td>
<td>30</td>
<td>21.5K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.25</td>
<td>$0.23</td>
<td>$0.23</td>
<td>$22.00</td>
<td>$67.9K</td>
<td>22.5K</td>
<td>13.4K</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
After a thorough review of the options trading surrounding Teva Pharmaceutical Indus, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Teva Pharmaceutical Indus</h3>
<ul>
<li>With a trading volume of 5,067,042, the price of TEVA is up by 0.3%, reaching $16.62.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Teva Pharmaceutical Indus Unusual Options Activity

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) revealed 9 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $425,757, and 3 were calls, valued at $94,635.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $19.0 for Teva Pharmaceutical Indus, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with a total volume of 8,643.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Teva Pharmaceutical Indus's big money trades within a strike price range of $15.0 to $19.0 over the last 30 days.
<h3>Teva Pharmaceutical Indus Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730996177_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.03</td>
<td>$2.02</td>
<td>$2.02</td>
<td>$17.00</td>
<td>$109.1K</td>
<td>1.1K</td>
<td>540</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.6</td>
<td>$0.51</td>
<td>$0.6</td>
<td>$17.00</td>
<td>$89.4K</td>
<td>12.6K</td>
<td>1.5K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.6</td>
<td>$1.56</td>
<td>$1.56</td>
<td>$18.00</td>
<td>$69.5K</td>
<td>5.6K</td>
<td>999</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.63</td>
<td>$1.55</td>
<td>$1.56</td>
<td>$18.00</td>
<td>$62.5K</td>
<td>5.6K</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.56</td>
<td>$1.53</td>
<td>$1.56</td>
<td>$18.00</td>
<td>$60.0K</td>
<td>5.6K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Teva Pharmaceutical Indus Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,427,612, the price of TEVA is up by 0.52%, reaching $17.52.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>What The Experts Say On Teva Pharmaceutical Indus</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $21.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $25. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Teva Pharmaceutical Indus with a target price of $18. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on TEVA Options

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $4.12 billion</a>.
Revenues increased 13% year-over-year and 15% on constant currency. This was mainly due to higher revenues from generic products in all segments (i.e., Austedo in the U.S. segment), and the sale of product rights in Europe and <a href="https://www.benzinga.com/pressreleases/24/11/g41769774/teva-announces-strong-financial-results-for-the-third-quarter-of-2024-led-by-generics-performance-" target="_blank" rel="noreferrer noopener">International Markets segments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug</a>
Generics business grows across all regions — increased by 30% in the U.S., 8% in Europe, and 13% in International Markets, in local currency terms compared to Q3 2023.
Generic products revenues in the U.S. segment (including biosimilars) were $1.09 billion, up 30% year over year, the majority of which was driven by higher revenues from lenalidomide capsules (the generic version of Bristol Myers Squibb &amp; Co&#8217;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) Revlimid), and the remaining, primarily by the launch of liraglutide injection 1.8mg — an authorized generic of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Victoza — and higher revenues from epinephrine injectable solution (the generic equivalent of EpiPen and EpiPen Jr).
<ul>
<li>Austedo U.S. revenues increased 28% to $435 million. Ajovy's global revenues increased by 21% to $137 million.</li>
<li>Uzedy&#8217;s U.S. revenues of $35 million.</li>
<li>Teva says its intention to divest Teva API is on track, targeting completion in the first half of 2025.</li>
<li>Adjusted EPS of 69 cents, higher than 60 cents a year ago, beating the consensus of 66 cents.</li>
<li>Adjusted gross profit margin&nbsp;was 53.7% in the third quarter of 2024, compared to 53.5% in the third quarter of 2023.</li>
<li>Adjusted operating margin reached 28%, down from 26.5% a year ago.</li>
<li>Adjusted EBITDA&nbsp;was $1.34 billion in the third quarter of 2024, an increase of 17%.</li>
</ul>
Outlook:&nbsp;Teva expects fiscal year 2024 revenues of $16.1 billion-$16.5 billion versus <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40071226/teva-beats-q2-estimates-raises-annual-outlook-on-strong-generic-austedo-sales" rel="noreferrer noopener">prior guidance of</a> $16.0 billion—$16.4 billion and consensus of $16.256 billion.
The generic pharma player expects 2024 adjusted EPS of $2.40-$2.50 versus prior guidance of $2.30-$2.50 and consensus of $2.45.
The company raised 2024 Uzedy sales guidance from around $80 million to approximately $100 million.
Price Action: Teva stock is up 1.76% at $19.10 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41773974/energy-drink-maker-celsius-misses-on-q3-earnings-as-supply-chain-optimization-weighs-on-margins-det" target="_blank" rel="noreferrer noopener">Energy Drink Maker Celsius Misses On Q3 Earnings As Supply Chain Optimization Weighs On Margins: Details</a></li>
</ul>

Guidance

Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast

Teva Pharmaceutical CEO Francis Says Expects Generics Prices To Be Pushed Down In 2025

Teva shares are trading higher after the company reported better-than-expected Q3 earnings and raised its guidance.

Teva Forecasts 2024 Revenues Of $16.1B-$16.5B Versus Prior Guidance Of $16.0B-$16.4B And Consensus Of $16.256B

Outlook for 2024 Non-GAAP Results
<figure class="table"> 
<table>
<tbody>
<tr>
<td>$ billions, except EPS or as noted</td>
<td>November 2024 Outlook</td>
<td>July 2024 Outlook</td>
<td>February 2024 Outlook</td>
</tr>
<tr>
<td>Revenues&#x2A;</td>
<td>$16.1 - $16.5</td>
<td>$16.0 - $16.4</td>
<td>$15.7 - $16.3</td>
</tr>
<tr>
<td>AUSTEDO ($m)&#x2A;</td>
<td>~1,600</td>
<td>~1,600</td>
<td>~1,500</td>
</tr>
<tr>
<td>AJOVY ($m)&#x2A;</td>
<td>~500</td>
<td>~500</td>
<td>~500</td>
</tr>
<tr>
<td>UZEDY ($m)&#x2A;</td>
<td>~100</td>
<td>~80</td>
<td>~80</td>
</tr>
<tr>
<td>COPAXONE ($m)&#x2A;</td>
<td>~500</td>
<td>~450</td>
<td>~400</td>
</tr>
<tr>
<td>Operating Income</td>
<td>4.2 - 4.5</td>
<td>4.1 - 4.5</td>
<td>4.0 - 4.5</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>4.7 - 5.0</td>
<td>4.6 - 5.0</td>
<td>4.5 - 5.0</td>
</tr>
<tr>
<td>Finance Expenses ($m)</td>
<td>~1,000</td>
<td>~1,000</td>
<td>~1,000</td>
</tr>
<tr>
<td>Tax Rate</td>
<td>14% - 17%</td>
<td>14% - 17%</td>
<td>14% - 17%</td>
</tr>
<tr>
<td>Diluted EPS ($)</td>
<td>2.40 - 2.50</td>
<td>2.30 - 2.50</td>
<td>2.20 - 2.50</td>
</tr>
<tr>
<td>Free Cash Flow&#x2A;&#x2A;</td>
<td>1.7 - 2.0</td>
<td>1.7 - 2.0</td>
<td>1.7 - 2.0</td>
</tr>
<tr>
<td>CAPEX&#x2A;</td>
<td>~0.5</td>
<td>~0.5</td>
<td>~0.5</td>
</tr>
<tr>
<td>Foreign Exchange</td>
<td colspan="2">Volatile swings in FX can negatively impact revenue and income</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.66 by 4.55 percent. The company reported quarterly sales of $4.33 billion which beat the analyst consensus estimate of $4.12 billion by 5.16 percent. This is a 12.52 percent increase over sales of $3.85 billion the same period last year.

Teva Pharmaceutical Indus Q3 2024 Adj EPS $0.69 Beats $0.66 Estimate, Sales $4.33B Beat $4.12B Estimate

Biggest stock movers Tuesday: TSLA, TEVA, ZYME, EVGO, and more

Teva (TEVA) is up 19.2%, or $3.17 to $19.68. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Teva rises 19.2%

Teva (TEVA) is up 21.4%, or $3.54 to $20.05. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Teva rises 21.4%

BofA raised the firm's price target on Teva (TEVA) to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the str...

Teva price target raised to $25 from $23 at BofA

BTIG analyst Julian Harrison notes that Teva‘s (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A ass...

Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG

TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sano...

TD says Spyre has 'superior TL1A program' after Teva data

Drugmakers Teva Pharmaceutical ($TEVA) and Sanofi ($SNY) announced earlier today that their experimental antibody therapy, duvakitug, showed impres...

Teva and Sanofi (SNY) Jump amid Impressive Drug Results

J.P. Morgan analyst Chris Schott maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company's shares closed ye...

Teva Pharmaceutical (TEVA) Gets a Hold from J.P. Morgan

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilent (A – Research Report) and Teva Pharmaceutical (TEVA – Res...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A) and Teva Pharmaceutical (TEVA)

Barclays analyst Balaji Prasad raised the firm's price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The firm...

Teva price target raised to $28 from $25 at Barclays

EVGO

MITK

PLTR

RCAT

SNYNF

SYRE

ZYME

Legal

Press Releases

Teva Statement on European Commission Decision; Company to Appeal

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Teva Pharmaceutical Indus

매도 수량

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌